DeutschNewstral
Article
huffingtonpost.ca on 2015-09-25 21:59
Alexion Pharmaceuticals Challenges Ottawa's Ability To Control Patent Drug Prices
Related news
Alexion Pharmaceuticals sues Canada over $700K a year cost for SolirisCBC
U.S. maker of $500,000 drug challenges Ottawa’s ability to control drug pricesThe Globe and Mail- Alexion Pharmaceuticals ordered to lower price of Soliris in CanadaCBC
CFO Moves: Alexion Pharmaceuticalsblogs.wsj.com- MAstraZeneca’s $39 billion takeover of U.S.-based Alexion Pharmaceuticals examined by U.K. regulatormarketwatch.com
Belcher Pharmaceuticals’ Patent Held Unenforceable by the Federal Circuitjdsupra.com
Why Alexion Pharmaceuticals Is OvervaluedForbes- SWAT teams and patent trolls: inside Ottawa's IP plan to promote Canadian innovatorsCBC
Alexion Pharmaceuticals announces new leadership appointmentswtnh.com- More top executives leaving Alexion Pharmaceuticalswtnh.com
Alexion Pharmaceuticals Inc. moving headquarters to Boston.Merced Sun-Star- U.S. Justice Department Investigating Alexion Pharmaceuticalsblogs.wsj.com
Alexion Pharmaceuticals Names COO to CEOwsj.com- Why AstraZeneca Wants To Buy Alexion PharmaceuticalsForbes
- CFO Moves: Alexion Pharmaceuticals, Chemring Groupblogs.wsj.com
- IAstraZeneca to acquire Alexion Pharmaceuticals for £29.50 billioninvezz.com
- AAlexion Pharmaceuticals is moving its headquarters to Bostonapnewsarchive.com
- BAlexion Pharmaceuticals Beats Earnings Estimates but Cuts Guidancebarrons.com
- Alexion Pharmaceuticals: Good Growth But Out Of FavorForbes
Former Alexion executive to take helm at Agios Pharmaceuticalsbizjournals.com